Siplizumab for Sickle Cell Disease Transplant
Stopped early · Phase 1/Phase 2
Conditions studied: Anemia, Sickle Cell
In brief
The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure. The main goals of this study are : * To determine if acute GVHD occurs and how severe the acute GVHD is in subjects receiving the study drug * To determine if graft failure occurs in subjects receiving the study drugs In this study, participants will receive 5 infusions of the study drug, siplizumab, while getting a stem cell transplant for SCD. Before siplizumab infusion, participants will be given medications to reduce the risks of allergic reaction to the drug.
Key facts
- Study ID
- NCT06078696
- Run by
- Columbia University
- People needed
- 1
- Starts
- 2023-09-28
- Expected to finish
- 2025-12-11
- Last updated by the study team
- 2026-06-10
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Columbia University Irving Medical Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.